VBI Vaccines (VBIV)
(Delayed Data from NSDQ)
$0.64 USD
+0.01 (1.37%)
Updated May 20, 2024 04:00 PM ET
After-Market: $0.64 0.00 (0.22%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VBIV 0.64 +0.01(1.37%)
Will VBIV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for VBIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VBIV
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates
VBIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Misses Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Other News for VBIV
VBI Vaccines Reports First Quarter 2024 Financial Results
VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024
VBI Vaccines GAAP EPS of -$0.73 misses by $0.20, revenue of $1.21M misses by $1.64M
VBI Vaccines’ Revenue Soars, Promising Vaccine Trials
VBI Vaccines Updates Share Sale Agreements and Partnerships